Ryan B M, Russel M G V M, Langholz E, Stockbrugger R W
Department of Gastroenterology, University Hospital Maastricht, Maastricht, The Netherlands.
Am J Gastroenterol. 2003 Aug;98(8):1682-7. doi: 10.1111/j.1572-0241.2003.07599.x.
Inflammatory bowel disease (IBD) is associated with an increased risk of developing intestinal cancer at sites of chronic inflammation. Aminosalicylates, including both sulfasalazine and mesalamine, are the most commonly prescribed anti-inflammatory agents prescribed in IBD. On balance, the body of literature to date suggests that aminosalicylates confer some protection against the development of colonic neoplasia in patients with IBD and in a variety of models, including in the noninflamed gut. This latter observation implies that aminosalicylates may be of chemopreventive value in normal as well as IBD individuals. The current review examines and gives an overview of the evidence from a variety of sources, including epidemiological, in vivo and in vitro studies that have investigated the potential anticancer effects of aminosalicylates.
炎症性肠病（IBD）与慢性炎症部位发生肠癌的风险增加相关。氨基水杨酸类药物，包括柳氮磺胺吡啶和美沙拉嗪，是IBD中最常用的抗炎药物。总体而言，迄今为止的文献表明，氨基水杨酸类药物在IBD患者以及包括非炎症性肠道在内的多种模型中，对结肠肿瘤的发生具有一定的保护作用。后一项观察结果表明，氨基水杨酸类药物在正常人和IBD患者中可能具有化学预防价值。本综述考察并概述了来自各种来源的证据，包括流行病学、体内和体外研究，这些研究探讨了氨基水杨酸类药物的潜在抗癌作用。
